CDK9 inhibitors are being tested for the treatment of multiple malignancies, including multiple myeloma, acute myeloid leukemia, prostate cancer, and hepatocellular carcinoma, making CDK9 a valid potential therapeutic target and a novel prognostic marker [16,17,18,19]. The gene discussed is CDK9; the disease is prostate cancer.